Curated Wealth Partners LLC Reduces Holdings in Pfizer Inc. $PFE

Curated Wealth Partners LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 6.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 41,822 shares of the biopharmaceutical company’s stock after selling 2,651 shares during the quarter. Curated Wealth Partners LLC’s holdings in Pfizer were worth $1,014,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter valued at $28,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter valued at $28,000. WPG Advisers LLC purchased a new stake in shares of Pfizer during the first quarter valued at $35,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock opened at $24.53 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82. The firm has a 50-day simple moving average of $24.88 and a two-hundred day simple moving average of $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $139.44 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PFE. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.